| Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism HM Itkonen, SS Gorad, DY Duveau, SES Martin, A Barkovskaya, ... Oncotarget 7 (11), 12464, 2016 | 83 | 2016 |
| Metabolic reprogramming supports the invasive phenotype in malignant melanoma IJ Bettum, SS Gorad, A Barkovskaya, S Pettersen, SA Moestue, ... Cancer letters 366 (1), 71-83, 2015 | 80 | 2015 |
| Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition S Halldorsson, N Rohatgi, M Magnusdottir, KS Choudhary, T Gudjonsson, ... Cancer letters 396, 117-129, 2017 | 58 | 2017 |
| Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors K Seip, KG Fleten, A Barkovskaya, V Nygaard, MH Haugen, ... Oncotarget 7 (15), 19997, 2016 | 43 | 2016 |
| O-GlcNAc transferase inhibition differentially affects breast cancer subtypes A Barkovskaya, K Seip, B Hilmarsdottir, GM Maelandsmo, SA Moestue, ... Scientific reports 9 (1), 5670, 2019 | 29 | 2019 |
| Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells A Barkovskaya, K Seip, L Prasmickaite, IG Mills, SA Moestue, HM Itkonen Scientific Reports 10 (1), 16992, 2020 | 23 | 2020 |
| Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition AM Waters, TO Khatib, B Papke, CM Goodwin, GA Hobbs, JN Diehl, ... Cell reports 35 (13), 2021 | 18 | 2021 |
| Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen A Barkovskaya, CM Goodwin, K Seip, B Hilmarsdottir, S Pettersen, ... Molecular Oncology 15 (8), 2026-2045, 2021 | 5 | 2021 |
| Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. Oncotarget 7, 12464–12476 HM Itkonen, SS Gorad, DY Duveau, SE Martin, A Barkovskaya, TF Bathen, ... | 5 | 2016 |
| O-GlcNAc transferase inhibition in breast cancer cells A Barkovskaya, L Prasmickaite, DY Duveau, IG Mills, GM Mælandsmo, ... Cancer Research 77 (13_Supplement), 1131-1131, 2017 | 1 | 2017 |
| Proteoglycans as Mediators of Cancer Tissue Mechanics BA Buffone Jr Alexander, Žídek Martin, Weaver Valerie Frontiers in cell and developmental biology 8 (569377), 2020 | | 2020 |
| Targeted Cancer Therapy: Overcoming Plasticity and Resistance A Barkovskaya NTNU, 2019 | | 2019 |
| Metabolic reprogramming in EMT-targeting regulatory nodes in mesenchymal cells B Hilmarsdottir, S Halldorsson, MT Grinde, A Barkovskaya, S Pettersen, ... Cancer Research 77 (13_Supplement), 4412-4412, 2017 | | 2017 |
| Inhibition of O-GlcNAc transferase in tamoxifen resistant breast cancer cells A Barkovskaya, L Prasmickaite, IG Mills, GM Mælandsmo, SA Moestue, ... Cancer Research 76 (14_Supplement), 3737-3737, 2016 | | 2016 |
| Fibroblast-induced switching to the invasive phenotype and PI3K-mTOR signaling protects melanoma cells from BRAF inhibitors K Seip, KG Fleten, A Barkovskaya, V Nygaard, MH Haugen, ... Cancer Research 76 (14_Supplement), 927-927, 2016 | | 2016 |
| Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors K Vasiliauskaite, KG Fleten, A Barkovskaya, V Nygaard, MH Haugen, ... Impact Journals, 2016 | | 2016 |
| How stromal cells assist tumor cells modulating the response to BRAF inhibition; impact for treatment of site-specific metastasis K Vasiliauskaite, KG Fleten, A Barkovskaya, B Engesaeter, ... CLINICAL & EXPERIMENTAL METASTASIS 32 (3), 244-244, 2015 | | 2015 |
| Fibroblasts Promote Resistance to BRAF inhibition; The Role of Molecular, Signaling and Metabolic Changes in Melanoma A Barkovskaya | | 2015 |
